Reverse hexagonal mesophase (HII) liquid crystals provide multi-component hexagonal systems for use in solubilizing and/or protecting from degradation one or more bio-macromolecule and/or active material, and relates to therapeutic and non-therapeutic applications, such as an oral delivery system, where the mesophase is adapted for oral administration. The present invention provides the formation of mesophase systems of ternary glycerol monooleate (GMO)/water combinations which comprise at least one triglyceride or an equivalent thereof. At least one biomacromolecule or drug is incorporated in the mesophase of a pharmaceutical composition or oral delivery system.